Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma

Gynecologic Oncology

Volumn 62, Issue 2, 1996, Pages 192-198

  Hamel, Nicholas W ^a   Sebo, Thomas J ^a   Wilson, Timothy O ^a   Keeney, Gary L ^a   Roche, Patrick C ^a   Suman, Vera J ^a   Hu, Theresa C ^a   Podratz, Karl C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; PROTEIN ANTIBODY; PROTEIN P53;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; ENDOMETRIUM CARCINOMA; FEMALE; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOPEROXIDASE STAINING; MAJOR CLINICAL STUDY; ONCOGENE NEU; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

EID: 0030220134     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.0214     Document Type: Article

References (49)

1. 1. Boring, C. C., Squires, T. S., Tong, T., and Montgomery, S. Cancer statistics, 1994, Ca Cancer J. Clin. 44, 7-26 (1994).
2. 2. DiSaia, P. J., and Creasman, W. T. Management of endometrial adenocarcinoma stage I with surgical staging followed by tailored adjuvant radiation therapy, Clin. Obstet. Gynecol. 13, 751-765 (1986).
3. 3. Malkasian, G. D., Jr., McDonald, T. W., and Pratt, J. H. Carcinoma of the endometrium: Mayo Clinic experience, Mayo Clin. Proc. 52, 175-180 (1977).
4. 4. Malkasian, G. D., Jr. Carcinoma of the endometrium: Effect of stage and grade on survival, Cancer 41, 996-1001 (1978).
5. 5. Genest, P., Drouin, P, Gerig, L., Girard, A., Stewart, D., and Prefontaine, M. Prognostic factors in early carcinoma of the endometrium, Am. J. Clin. Oncol. 10, 71-77 (1987).
6. 6. Imachi, M., Tsukamoto, N., Matsuyama, T., and Nakano, H. Peritoneal cytology in patients with endometrial carcinoma, Gynecol. Oncol. 30, 76-86 (1988).
7. 7. Wilson, T. O., Podratz, K. C., Gaffey, T. A., Malkasian, G. D., Jr., O'Brien, P. C., and Naessens, J. M. Evaluation of unfavorable histologic subtypes in endometrial adenocarcinoma, Am. J. Obstet. Gynecol. 162, 418-423 (1990).
8. 8. Berchuck, A., Rodriguez, G., Kinney, R. B., Soper, J. T., Dodge, R. K., Clarke-Pearson, D. L., and Bast, R. C., Jr. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease, Am. J. Obstet. Gynecol. 164, 15-21 (1991).
9. 9. Bigsby, R. M., Li, A. X., Bomalaski, J., Stehman, F. B., Look, K. Y., and Sutton, G. P. Immunohistochemical study of HER-2/neu, epidermal growth factor receptor, and steroid receptor expression in normal and malignant endometrium, Obstet. Gynecol. 79, 95-100 (1992).
10. 10. Hetzel, D. J., Wilson, T. O., Keeney, G. L., Roche, P. C., Cha, S. S., and Podratz, K. C. HER-2/neu expression: A major prognostic factor in endometrial cancer, Gynecol. Oncol. 47, 179-185 (1992).
11. 11. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science 235, 177-182 (1987).
12. 12. Steinmeyer, K., Maacke, H., and Deppert, W. Cell cycle control by p53 in normal (3T3) and chemically transformed (Meth A) mouse cells. I. Regulation of p53 expression, Oncogene 5, 1691-1699 (1990).
13. 13. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage, Cancer Res. 51, 6304-6311 (1991).
14. 14. Chen, P. L., Chen, Y. M., Bookstein, R., and Lee, W. H. Genetic mechanisms of tumor suppression by the human p 53 gene, Science 250, 1576-1580 (1990).
15. 15. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers, Science 253, 49-53 (1991).
16. 16. Chang, K., Ding, I., Kern, F. G., and Willingham, M. C. Immunohistochemical analysis of p53 and HER-2/neu proteins in human tumors, J. Histochem. Cytochem. 39, 1281-1287 (1991).
17. 17. Bartek, J., Bartkova, J., Vojtesek, B., Staskova, Z., Lukas, J., Rejthar, A., Kovarik, J., Midgley, C. A., Gannon, J. V., and Lane, D. P. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies, Oncogene 6, 1699-1703 (1991).
18. 18. Kraiss, S., Spiess, S., Reihsaus, E., and Montenarh, M. Correlation of metabolic stability and altered quaternary structure of oncoprotein p53 with cell transformation, Exp. Cell Res. 192, 157-164 (1991).
19. 19. Okamoto, A., Sameshima, Y., Yamada, Y., Teshima, S., Terashima, Y., Terada, M., and Yokota, J. Allelic loss on chromosome 17p and p53 mutations in human endometrial carcinoma of the uterus, Cancer Res. 51, 5632-5635 (1991).
20. 20. Kohler, M. F., Berchuck, A., Davidoff, A. M., Humphrey, P. A., Dodge, R. K., Iglehart, J. D., Soper, J. T., Clarke-Pearson, D. L., Bast, R. C., Jr., and Marks, J. R. Overexpression and mutation of p53 in endometrial carcinoma, Cancer Res. 52, 1622-1627 (1992).
21. 21. Leiserowitz, G. S., Harris, S. A., Subramaniam, M., Keeney, G. L., Podratz, K. C., and Spelsberg, T. C. The proto-oncogene c-fms is overexpressed in endometrial cancer, Gynecol. Oncol. 49, 190-196 (1993).
22. 22. Creasman, W. T., Soper, J. T., McCarty, K. S., Jr., McCarty, K. S., Sr., Hinshaw, W., and Clarke-Pearson, D. L. Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma, Am. J. Obstet. Gynecol. 151, 922-932 (1985).
23. 23. Britton, L. C., Wilson, T. O., Gaffey, T. A., Lieber, M. M., Wieand, H. S., and Podratz, K. C. Flow cytometric DNA analysis of stage I endometrial carcinoma, Gynecol. Oncol. 34, 317-322 (1989).
24. 24. Stendahl, U., Strang, P., Wagenius, G., Bergstrom, R., and Tribukait, B. Prognostic significance of proliferation in endometrial adenocarcinomas: A multivariate analysis of clinical and flow cytometric variables, Int. J. Gynecol. Pathol. 10, 271-284 (1991).
25. 25. Dyas, C. H., Simmons, T. K., Ellis, C. N., Austin, J. M., Jr., Partridge, E. E., Jr., Kilgore, L. C., Reading, C., Nelson, K., and Blakemore, W. S. Effect of deoxyribonucleic acid ploidy status on survival of patients with carcinoma of the endometrium, Surg. Gynecol. Obstet. 174, 133-136 (1992).
26. 26. Podratz, K. C., Wilson, T. O., Gaffey, T. A., Cha, S. S., and Katzmann, J. A. Deoxyribonucleic acid analysis facilitates the pretreatment identification of high-risk endometrial cancer patients, Am. J. Obstet. Gynecol. 168, 1206-1213 (1993).
27. 27. Bravo, R., Frank, R., Blundell, P. A., and Macdonald-Bravo, H. Cyclin/ PCNA is the auxiliary protein of DNA polymerase-delta, Nature 326, 515-517 (1987).
28. 28. Dawson, A. E., Norton, J. A., and Weinberg, D. S. Comparative assessment of proliferation and DNA content in breast carcinoma by image analysis and flow cytometry, Am. J. Pathol. 136, 1115-1124 (1990).
29. 29. Battersby, S., and Anderson, T. J. Correlation of proliferative activity in breast tissue using PCNA/cyclin, Hum. Pathol. 21, 781 (1990). [Letter to Editor]
30. 30. Landberg, G., and Roos, G. Expression of proliferating cell nuclear antigen (PCNA) and Ki-67 antigen in human malignant hematopoietic cells, Acta Oncol. 30, 917-921 (1991).
31. 31. Dervan, P. A., Magee, H. M., Buckley, C., and Carney, D. N. Proliferating cell nuclear antigen counts in formalin-fixed paraffin-embedded tissue correlate with Ki-67 in fresh tissue, Am. J. Clin. Pathol. 97(Suppl. 1), S21-S28 (1992).
32. 32. Kamel, O. W., LeBrun, D. P., Davis, R. E., Berry, G. J., and Warnke, R. A. Growth fraction estimation of malignant lymphomas in formalin-fixed paraffin-embedded tissue using anti-PCNA/cyclin 19A2. Correlation with Ki-67 labeling, Am. J. Pathol. 138, 1471-1477 (1991).
33. 33. Leonardi, E., Girlando, S., Serio, G., Mauri, F. A., Perrone, G., Scampini, S., Dalla Palma, P., and Barbareschi, M. PCNA and Ki67 expression in breast carcinoma: Correlations with clinical and biological variables, J. Clin. Pathol. 45, 416-419 (1992).
34. 34. Hall, P. A., Levison, D. A., Woods, A. L., Yu, C. C., Kellock, D. B., Watkins, J. A., Barnes, D. M., Gillett, C. E., Camplejohn, R., Dover, R., Waseem, N. H., and Lane, D. P. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: An index of cell proliferation with evidence of deregulated expression in some neoplasms, J. Pathol. 162, 285-294 (1990).
35. 35. Hartman, L. C., Sebo, T. J., Kamel, N. A., Podratz, K. C., Cha, S. S., Wieand, H. S., Keeney, G. L., and Roche, P. C. Proliferating cell nuclear antigen in epithelial ovarian cancer: Relation to results at second-look laparotomy and survival, Gynecol. Oncol. 47, 191-195 (1992).
36. 36. Hsu, S. M., Raine, L., and Fanger, H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures, J. Histochem. Cytochem. 29, 577-580 (1981).
37. 37. Peto, R., and Peto, J. Asymptotically efficient rank invariant procedures (with discussion), J. R. Stat. Soc. A 135, 185-207 (1972).
38. 38. Gehan, E. A. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples, Biometrika 52, 203-223 (1965).
39. 39. Cox, D. R. Regression models and life-tables (with discussion), J. R. Stat. Soc. B 34, 187-220 (1972).
40. 40. Khalifa, M. A., Mannel, R. S., Haraway, S. D., Walker, J., and Min, K. W. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas, Gynecol. Oncol. 53, 84-92 (1994).
41. 41. Yu, C. C., Wilkinson, N., Brito, M. J., Buckley, C. H., Fox, H., and Levison, D. A. Patterns of immunohistochemical staining for proliferating cell nuclear antigen and p53 in benign and neoplastic human endometrium, Histopathology 23, 367-371 (1993).
42. 42. Schofield, J. B., Mansi, J., Camplejohn, R. S., Lane, D. P., and Fisher, C. Proliferating cell nuclear antigen and S phase fraction in endometrial stromal sarcoma, J. Clin. Pathol. 45, 664-667 (1992).
43. 43. Yabushita, H., Masuda, T., Sawaguchi, K., Noguchi, M., and Nakanishi, M. Growth potential of endometrial cancers assessed by a Ki-67 Ag/ DNA dual-color flow-cytometric assay, Gynecol. Oncol. 44, 263-267 (1992).
44. 44. Lukes, A. S., Kohler, M. F., Pieper, C. F., Kerns, B. J., Bentley, R., Rodriguez, G. C., Soper, J. T., Clarke-Pearson, D. L., Bast, R. C., Jr., and Berchuck, A. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer, Cancer 73, 2380-2385 (1994).
45. 45. Ito, K., Watanabe, K., Nasim, S., Sasano, H., Sato, S., Yajima, A., Silverberg, S. G., and Garrett, C. T. Prognostic significance of p53 overexpression in endometrial cancer, Cancer Res. 54, 4667-4670 (1994).
46. 46. Pisani, A. L., Barbuto, D. A., Chen, D., Ramos, L., Lagasse, L. D., and Karlan, B. Y. HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma. Obstet. Gynecol. 85, 729-734 (1995).
47. 47. Enomoto, T., Fujita, M., Inoue, M., Rice, J. M., Nakajima, R., Tanizawa, O., and Nomura, T. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium, Cancer Res. 53, 1883-1888 (1993).
48. 48. Risinger, J. I., Dent, G. A., Ignar-Trowbridge, D., McLachlan, J. A., Tsao, M. S., Senterman, M., and Boyd, J. p53 gene mutations in human endometrial carcinoma, Mol. Carcinog. 5, 250-253 (1992).
49. 49. Wachtel, S. S., Wachtel, G., Shulman, L. P., Phillips, O., Miller, B., and Photopulos, G. Identification of p53 mutations in endometrial adenocarcinoma by polymerase chain reaction-single-strand conformation polymorphism, J. Soc. Gynecol. Invest. 1, 234-237 (1994).